Potential survival advantage with early androgen deprivation for biochemical failure after external beam radiotherapy: The importance of accurately defining biochemical disease status

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 2, 2004, Pages 453-462

  Kestin, Larry L ^a   Vicini, Frank A ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical failure; Hormonal therapy; Prostate; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANTIGENS; BIOCHEMISTRY; CLINICAL LABORATORIES; DOSIMETERS; DRUG DOSAGE; PATIENT MONITORING;

ANDROGEN DEPRIVATION (AD); BIOCHEMICAL FAILURE (BF); EXTERNAL BEAM RADIOTHERAPY; PROSTATE CANCER;

RADIOTHERAPY;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CAUSE OF DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION BEAM; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT FAILURE;

EID: 4544360999     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.03.013     Document Type: Article

References (60)

1. Hanlon A.L., Moore D.F., Hanks G.E. Modeling postradiation prostate specific antigen level kinetics Predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. Cancer. 83:1998;130-134
2. Hanlon A.L., Pinover W.H., Horwitz E.M., et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 50:2001;845-849
3. Zagars G.K., Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 72:1993;832-842
4. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221
5. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-1041
6. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt) 2000;14:267-268, 280
7. Johnstone P.A. Biochemical failure after definitive therapy of prostate cancer Defining the chicken switch. Int J Radiat Oncol Biol Phys. 55:2003;859-860
8. Vicini F.A., Kestin L.L., Martinez A.A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer. 88:2000;2305-2318
9. Kestin L.L., Vicini F.A., Martinez A.A. Practical application of biochemical failure definitions What to do and when to do it. Int J Radiat Oncol Biol Phys. 53:2002;304-315
10. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 36:1996;565-571
11. Kestin L.L., Vicini F.A., Ziaja E.L., et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer. 86:1999;1557-1566
12. Vicini F.A., Kestin L.L., Martinez A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 45:1999;553-561
13. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170
15. Cox D.R. Regression models and life-tables. J R Stat Soc B. 34:1972;187-220
16. Critz F.A., Levinson A.K., Williams W.H., et al. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol. 161:1999;1199-1203
17. Crook J.M., Choan E., Perry G.A., et al. Serum prostate-specific antigen profile following radiotherapy for prostate cancer Implications for patterns of failure and definition of cure. Urology. 51:1998;566-572
18. Ennis R.D., Malyszko B.K., Heitjan D.F., et al. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 41:1998;511-517
19. Hanlon A.L., Hanks G.E. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 46:2000;559-566
20. Hodgson D.C., Catton C.N., Warde P., et al. The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy. Int J Radiat Oncol Biol Phys. 49:2001;957-963
21. Jani A.B., Chen M.H., Vaida F., et al. PSA-based outcome analysis after radiation therapy for prostate cancer A new definition of biochemical failure after intervention. Urology. 54:1999;700-705
22. Kattan M.W., Fearn P.A., Leibel S., et al. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 48:2000;1469-1474
23. Pickles T., Duncan G.G., Kim-sing C., et al. PSA relapse definitions - the Vancouver Rules show superior predictive power. Int J Radiat Oncol Biol Phys. 43:1999;699-700
24. Taylor J.M., Griffith K.A., Sandler H.M. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 50:2001;1212-1219
25. Nixon R.G., Wener M.H., Smith K.M., et al. Biological variation of prostate specific antigen levels in serum An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol. 157:1997;2183-2190
26. Willett C.G., Zietman A.L., Shipley W.U., et al. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol. 151:1994;1579-1581
27. Zietman A.L., Zehr E.M., Shipley W.U. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys. 43:1999;715-718
28. Moul JW. Rising PSA after local therapy failure: Immediate vs deferred treatment. Oncology (Huntingt) 1999;13:985-990, 993
29. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol. 163:2000;1632-1642
30. Partin AW, Hanks GE, Klein EA, et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Huntingt) 2002;16:1024-1038, 1042
31. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 20:2002;4567-4573
32. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999 Incidence. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2002
33. Amling C.L., Bergstralh E.J., Blute M.L., et al. Defining prostate specific antigen progression after radical prostatectomy What is the most appropriate cut point? J Urol. 165:2001;1146-1151
34. Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol. 36:1999;20-26
35. Schroder F.H. Endocrine treatment of prostate cancer Recent developments and the future. Part I: Maximal androgen blockage, early vs. delayed endocrine treatment and side-effects. BJU Int. 83:1999;161-170
36. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate Immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. J Urol. 166:2001;508-515
37. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235-246
38. Byar D.P. Proceedings The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 32:1973;1126-1130
39. Byar D.P. VACURG studies of conservative treatment. Scand J Urol Nephrol Suppl. 55:1980;99-102
40. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Agency for Health Care Policy and Research publication no. 99-E012. Bethesda, MD: United States Public Health Service, 1999
41. See W.A., Wirth M.P., McLeod D.G., et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer First analysis of the early prostate cancer program. J Urol. 168:2002;429-435
42. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300
43. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) A phase III randomised trial. Lancet. 360:2002;103-106
44. Hanks G.E., Lu J., Machtay M., et al. RTOG protocol 92-02 A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol. 19:2000;327a
45. Horwitz E.M., Winter K., Hanks G.E., et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long- term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 49:2001;947-956
46. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 49:2001;937-946
47. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 50:2001;1243-1252
48. Baert L.V., Goethuys H.J., de Ridder D.J., et al. Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-T3 but has no impact on PSA progression or survival in cT2-T3. J Urol. 159:1998;61
49. Klotz L., Gleave M., Goldenberg S.L. Neoadjuvant hormone therapy The Canadian trials. Mol Urol. 4:2000;233-237
50. Soloway M.S., Sharifi R., Wajsman Z., et al. Radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 months results. Br J Urol. 80:1997;259
51. Witjes W.P., Schulman C.C., Debruyne F.M.J., et al. Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma 3 to 4 years of follow-up of a European randomized study. J Urol. 159:1998;254
52. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788
53. Hanks G.E., D'Amico A., Epstein B.E., et al. Prostatic-specific antigen doubling times in patients with prostate cancer A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys. 27:1993;125-127
54. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 158:1997;1441-1445
55. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678
56. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597
57. Pruthi R.S., Johnstone I., Tu I.P., et al. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy Correlation with histologic characteristics of the primary cancer. Urology. 49:1997;737-742
58. Roberts S.G., Blute M.L., Bergstralh E.J., et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 76:2001;576-581
59. Sandler H.M., Dunn R.L., McLaughlin P.W., et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 48:2000;629-633
60. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 38:1997;941-947